[Form 4] BridgeBio Pharma, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Thomas Trimarchi, President and Chief Financial Officer of BridgeBio Pharma, Inc. (BBIO), reported a sale of 42,237 shares of common stock on 08/21/2025 at a weighted-average price of $49.4846 per share (sales ranged from $49.08 to $49.77). After the transaction he beneficially owned 421,081 shares, reported as a direct holding. The Form 4 discloses the transaction code as a sale and includes an explanatory footnote that the reporting person can provide a breakdown of shares sold at each price within the stated range.

Positive

• Clear disclosure of weighted-average sale price and price range with offer to provide per-price breakdown
• Continued ownership of 421,081 shares after the sale, indicating retained alignment with shareholders
• Form 4 filed by one reporting person, showing individual accountability

Negative

• Insider sale of 42,237 shares which may attract investor attention regarding executive selling activity

Insights

Securities Analyst

TL;DR: Routine insider sale by a senior executive; provides transparency but may prompt investor questions about timing.

The reported disposition of 42,237 shares by the company’s President and CFO appears to be a straightforward sale reported on Form 4. The filing supplies the weighted-average price and a price range, with the filer offering to provide a per-price breakdown on request, which supports disclosure quality. With 421,081 shares retained after the sale, the transaction reduces but does not eliminate the executive’s position, suggesting the sale is not an exit. This is a routine disclosure that is typically classified as non-material to company operations unless part of a broader pattern of selling by insiders.

Corporate Governance Expert

TL;DR: The Form 4 meets Section 16 disclosure norms; the sale is documented and the filer preserved a significant remaining stake.

The filing identifies the reporting person as both an officer and a director, which heightens the importance of clear disclosure. The Form 4 includes an explanatory footnote about the price range and offers further breakdowns on request, reflecting good compliance practice. Maintaining 421,081 shares post-sale indicates continued alignment with shareholder interests, though investors may monitor for additional filings to assess any trend in insider selling.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Trimarchi Thomas

(Last) (First) (Middle)

C/O BRIDGEBIO PHARMA, INC.

3160 PORTER DR., SUITE 250

(Street)

PALO ALTO CA 94304

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BridgeBio Pharma, Inc. [ BBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CFO

3. Date of Earliest Transaction (Month/Day/Year)
08/21/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/21/2025		S		42,237	D	$49.4846(1)	421,081	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the weighted average sale price of the shares sold from $49.08 to $49.77 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

	/s/ Damian Wilmot, Attorney-in-Fact	08/22/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did BridgeBio (BBIO) insider Thomas Trimarchi report on Form 4?

The filing reports that Thomas Trimarchi sold 42,237 shares of BridgeBio common stock on 08/21/2025 and owned 421,081 shares after the sale.

At what price were the BBIO shares sold by the reporting person?

The sale was at a weighted-average price of $49.4846 per share, with individual sales ranging from $49.08 to $49.77 per share.

What is the reporting person’s role at BridgeBio listed on the Form 4?

The Form 4 lists the reporting person as a Director and an Officer with the title President and CFO.

Does the Form 4 provide details on the number of shares sold at each price?

The footnote states the reported price is a weighted average and the reporting person will provide, upon request, a breakdown of the number of shares sold at each separate price within the stated range.

Was this Form 4 filed individually or jointly?

The Form 4 indicates it was filed by one reporting person.